Univariate analysis in the validation cohort
| Factor . | 5-y FFS, % . | P . | 5-y OS, % . | P . |
|---|---|---|---|---|
| Age (≥ 45 y) | ||||
| No | 74 | .49 | 91 | < .01 |
| Yes | 69 | 77 | ||
| Sex | ||||
| Female | 77 | .39 | 90 | .95 |
| Male | 70 | 88 | ||
| Stage 4 disease | ||||
| No | 77 | .01 | 91 | .12 |
| Yes | 57 | 84 | ||
| Albumin (< 4 g/dL) | ||||
| No | 74 | .96 | 87 | .9 |
| Yes | 73 | 89 | ||
| Hemoglobin (< 10.5 g/dL) | ||||
| No | 77 | .17 | 91 | .08 |
| Yes | 58 | 76 | ||
| WBC count (≥ 15 000/mm3) | ||||
| No | 73 | .85 | 89 | .67 |
| Yes | 76 | 86 | ||
| Lymphocyte count (< 600/mm3 or < 8%) | ||||
| No | 77 | .02 | 89 | .48 |
| Yes | 25 | 78 | ||
| IPS (≥ 3) | ||||
| No | 74 | .65 | 91 | .34 |
| Yes | 70 | 86 | ||
| CD68 | ||||
| ≤ 12.7% (CD68low) | 78 | .04 | 94 | < .01 |
| > 12.7% (CD68high) | 64 | 81 | ||
| CD163 | ||||
| ≤ 16.8% (CD163low) | 82 | < .01 | 96 | < .01 |
| > 16.8% (CD163high) | 63 | 81 | ||
| EBER | ||||
| Negative | 75 | .24 | 90 | .43 |
| Positive | 62 | 83 |
| Factor . | 5-y FFS, % . | P . | 5-y OS, % . | P . |
|---|---|---|---|---|
| Age (≥ 45 y) | ||||
| No | 74 | .49 | 91 | < .01 |
| Yes | 69 | 77 | ||
| Sex | ||||
| Female | 77 | .39 | 90 | .95 |
| Male | 70 | 88 | ||
| Stage 4 disease | ||||
| No | 77 | .01 | 91 | .12 |
| Yes | 57 | 84 | ||
| Albumin (< 4 g/dL) | ||||
| No | 74 | .96 | 87 | .9 |
| Yes | 73 | 89 | ||
| Hemoglobin (< 10.5 g/dL) | ||||
| No | 77 | .17 | 91 | .08 |
| Yes | 58 | 76 | ||
| WBC count (≥ 15 000/mm3) | ||||
| No | 73 | .85 | 89 | .67 |
| Yes | 76 | 86 | ||
| Lymphocyte count (< 600/mm3 or < 8%) | ||||
| No | 77 | .02 | 89 | .48 |
| Yes | 25 | 78 | ||
| IPS (≥ 3) | ||||
| No | 74 | .65 | 91 | .34 |
| Yes | 70 | 86 | ||
| CD68 | ||||
| ≤ 12.7% (CD68low) | 78 | .04 | 94 | < .01 |
| > 12.7% (CD68high) | 64 | 81 | ||
| CD163 | ||||
| ≤ 16.8% (CD163low) | 82 | < .01 | 96 | < .01 |
| > 16.8% (CD163high) | 63 | 81 | ||
| EBER | ||||
| Negative | 75 | .24 | 90 | .43 |
| Positive | 62 | 83 |